For HER2 + subtype, trastuzumab treatment targeting HER2 receptor that is expressed on the surface of tumor cells, represents a prototype of a successful treatment that has reversed the prognosis of HER2 + patients to more favorable outcome. Here, ERBB2 is linked to neoplasm.